Thoratec Receives CE Mark Approval for its HeartMate PHP™ Pump - Report on Thoratec Corp.

Jul 29, 2015, 09:20 ET from

NEW YORK, July 29, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Thoratec Corp. (NASDAQ: THOR). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:

Highlights from our THOR Report include:

  • HeartMate PHP Meets Requirements of European Community Directives - In its press release dated July 13, 2015, Thoratec Corporation (Thoratec) reported that its HeartMate PHP (Percutaneous Heart Pump) product has received CE Mark approval, thereby enabling the product's sale in the European Union and other international countries. Thoratec informed that HeartMate PHP is an acute cardiac assist device which is designed to uncouple the traditional relationship between size and flow in catheter-based support devices.
  • Clinical Trial's Primary Objective -As per the Company, the approval was based on data findings from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark trial. The primary objective of the trial was to evaluate the use of PHP to support patients going through from a high-risk PCI (percutaneous coronary intervention) procedure. As per the release, data from all 50 patients enrolled in the study will be presented later in 2015.
  • Commercialization Opportunity - Commenting upon the PHP's commercial acceptance and growth outlook, D. Keith Grossman, President and CEO stated that, "PHP is an entirely new opportunity for Thoratec.  Although the current catheter pump market outside the U.S. is relatively small, we look forward to gaining valuable clinical and commercial experience through a targeted European launch of HeartMate PHP in the coming months." Further, Thoratec intends to roll out HeartMate PHP in target markets through the rest of 2015 and 2016.
  • Other Clinical Trials on Track - On July 13, 2015, Cardiac Interventions Today, reported that Thoratec has recently received unconditional approval from the FDA for SHIELD II United States device exemption clinical trial and is expected to begin enrollment during the third quarter. In its earlier release dated July 6, 2015, Thoratec announced that the first HeartMate 3™ implant had been conducted via mini-thoracotomy. The Company reported that the implant starts a European study that seeks to assess outcomes and complications of using less invasive surgical placement through hemi-sternotomy and left thoracotomy techniques.

To find out how this influences our rating on Thoratec Corp., read the full report in its entirely here:

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.